Literature DB >> 21140215

Lubiprostone activates Cl- secretion via cAMP signaling and increases membrane CFTR in the human colon carcinoma cell line, T84.

Mei Ao1, Jayashree Venkatasubramanian, Chaiwat Boonkaewwan, Nivetha Ganesan, Asma Syed, Richard V Benya, Mrinalini C Rao.   

Abstract

BACKGROUND: Lubiprostone, used clinically (b.i.d.) to treat constipation, has been reported to increase transepithelial Cl(-) transport in T84 cells by activating ClC-2 channels. AIM: To identify the underlying signaling pathway, we explored the effects of short-term and overnight lubiprostone treatment on second messenger signaling and Cl(-) transport.
METHODS: Cl(-) transport was assessed either as I(sc) across T84 monolayers grown on Transwells and mounted in Ussing chambers or by the iodide efflux assay. [cAMP](i) was measured by enzyme immunoassay, and [Ca(2+)](i) by Fluo-3 fluorescence. Quantitation of apical cell surface CFTR protein levels was assessed by Western blotting and biotinylation with the EZ-Link Sulfo-NHS-LC-LC-Biotin. ClC-2 mRNA level was studied by RT-PCR.
RESULTS: Lubiprostone and the cAMP stimulator, forskolin, caused comparable and maximal increases of I(sc) in T84 cells. The I(sc) effects of lubiprostone and forskolin were each suppressed if the tissue had previously been treated with the other agent. These responses were unaltered even if the monolayers were treated with lubiprostone overnight. Lubiprostone-induced increases in iodide efflux were ~80% of those obtained with forskolin. Lubiprostone increased [cAMP](i). H89, bumetanide, or CFTR(inh)-172 greatly attenuated lubiprostone-stimulated Cl(-) secretion, whereas the ClC-2 inhibitor CdCl(2) did not. Compared to controls, FSK-treatment increased membrane-associated CFTR by 1.9 fold, and lubiprostone caused a 2.6-fold increase in apical membrane CFTR as seen by immunoblotting following cell surface biotinylation.
CONCLUSIONS: Lubiprostone activates Cl(-) secretion in T84 cells via cAMP, protein kinase A, and by increasing apical membrane CFTR protein.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21140215     DOI: 10.1007/s10620-010-1495-8

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  27 in total

1.  The voltage-dependent ClC-2 chloride channel has a dual gating mechanism.

Authors:  Leandro Zúñiga; María Isabel Niemeyer; Diego Varela; Marcelo Catalán; L Pablo Cid; Francisco V Sepúlveda
Journal:  J Physiol       Date:  2004-01-14       Impact factor: 5.182

2.  Mechanism underlying inhibition of intestinal apical Cl/OH exchange following infection with enteropathogenic E. coli.

Authors:  Ravinder K Gill; Alip Borthakur; Kim Hodges; Jerrold R Turner; Daniel R Clayburgh; Seema Saksena; Ayesha Zaheer; Krishnamurthy Ramaswamy; Gail Hecht; Pradeep K Dudeja
Journal:  J Clin Invest       Date:  2007-01-25       Impact factor: 14.808

Review 3.  Molecular targeting of CFTR as a therapeutic approach to cystic fibrosis.

Authors:  Margarida D Amaral; Karl Kunzelmann
Journal:  Trends Pharmacol Sci       Date:  2007-06-18       Impact factor: 14.819

4.  Recovery of mucosal barrier function in ischemic porcine ileum and colon is stimulated by a novel agonist of the ClC-2 chloride channel, lubiprostone.

Authors:  Adam J Moeser; Prashant K Nighot; Kory J Engelke; Ryuji Ueno; Anthony T Blikslager
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2006-10-19       Impact factor: 4.052

5.  Weanling, but not adult, rabbit colon absorbs bile acids: flux is linked to expression of putative bile acid transporters.

Authors:  Dirk Weihrauch; Jainuch Kanchanapoo; Mei Ao; Roli Prasad; Pawinee Piyachaturawat; Mrinalini C Rao
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2005-09-15       Impact factor: 4.052

6.  Chloride transporting capability of Calu-3 epithelia following persistent knockdown of the cystic fibrosis transmembrane conductance regulator, CFTR.

Authors:  L J MacVinish; G Cope; A Ropenga; A W Cuthbert
Journal:  Br J Pharmacol       Date:  2007-03-05       Impact factor: 8.739

7.  Differences in Ca(2+) signaling underlie age-specific effects of secretagogues on colonic Cl(-) transport.

Authors:  J Venkatasubramanian; N Selvaraj; M Carlos; S Skaluba; M M Rasenick; M C Rao
Journal:  Am J Physiol Cell Physiol       Date:  2001-03       Impact factor: 4.249

8.  Stimulation of mucosal secretion by lubiprostone (SPI-0211) in guinea pig small intestine and colon.

Authors:  Guijun Fei; Yu-Zhong Wang; Sumei Liu; Hong-Zhen Hu; Guo-Du Wang; Mei-Hua Qu; Xi-Yu Wang; Yun Xia; Xiaohong Sun; Laura M Bohn; Helen J Cooke; Jackie D Wood
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-01-29       Impact factor: 4.052

9.  Activation of prostaglandin EP receptors by lubiprostone in rat and human stomach and colon.

Authors:  A K Bassil; R A Borman; E M Jarvie; R J McArthur-Wilson; R Thangiah; E Z H Sung; K Lee; G J Sanger
Journal:  Br J Pharmacol       Date:  2008-03-10       Impact factor: 8.739

10.  SPI-0211 activates T84 cell chloride transport and recombinant human ClC-2 chloride currents.

Authors:  John Cuppoletti; Danuta H Malinowska; Kirti P Tewari; Qiu-Ju Li; Ann M Sherry; Myra L Patchen; Ryuji Ueno
Journal:  Am J Physiol Cell Physiol       Date:  2004-06-22       Impact factor: 4.249

View more
  25 in total

1.  Cholinergic signaling inhibits oxalate transport by human intestinal T84 cells.

Authors:  Hatim A Hassan; Ming Cheng; Peter S Aronson
Journal:  Am J Physiol Cell Physiol       Date:  2011-09-28       Impact factor: 4.249

Review 2.  New therapeutic perspectives in irritable bowel syndrome: Targeting low-grade inflammation, immuno-neuroendocrine axis, motility, secretion and beyond.

Authors:  Emanuele Sinagra; Gaetano Cristian Morreale; Ghazaleh Mohammadian; Giorgio Fusco; Valentina Guarnotta; Giovanni Tomasello; Francesco Cappello; Francesca Rossi; Georgios Amvrosiadis; Dario Raimondo
Journal:  World J Gastroenterol       Date:  2017-09-28       Impact factor: 5.742

3.  Oxalobacter formigenes-Derived Bioactive Factors Stimulate Oxalate Transport by Intestinal Epithelial Cells.

Authors:  Donna Arvans; Yong-Chul Jung; Dionysios Antonopoulos; Jason Koval; Ignacio Granja; Mohamed Bashir; Eltayeb Karrar; Jayanta Roy-Chowdhury; Mark Musch; John Asplin; Eugene Chang; Hatim Hassan
Journal:  J Am Soc Nephrol       Date:  2016-10-13       Impact factor: 10.121

4.  May the truth be with you: lubiprostone as EP receptor agonist/ClC-2 internalizing "inhibitor".

Authors:  Yasutada Akiba; Jonathan D Kaunitz
Journal:  Dig Dis Sci       Date:  2012-11       Impact factor: 3.199

Review 5.  American Gastroenterological Association technical review on constipation.

Authors:  Adil E Bharucha; John H Pemberton; G Richard Locke
Journal:  Gastroenterology       Date:  2013-01       Impact factor: 22.682

Review 6.  ClC-2 regulation of intestinal barrier function: Translation of basic science to therapeutic target.

Authors:  Younggeon Jin; Anthony T Blikslager
Journal:  Tissue Barriers       Date:  2015-11-13

7.  Lubiprostone decreases mouse colonic inner mucus layer thickness and alters intestinal microbiota.

Authors:  Mark W Musch; Yunwei Wang; Erika C Claud; Eugene B Chang
Journal:  Dig Dis Sci       Date:  2013-01-18       Impact factor: 3.199

8.  Dual activation of CFTR and CLCN2 by lubiprostone in murine nasal epithelia.

Authors:  Eric S Schiffhauer; Neeraj Vij; Olga Kovbasnjuk; Po Wei Kang; Doug Walker; Seakwoo Lee; Pamela L Zeitlin
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-01-11       Impact factor: 5.464

9.  Lubiprostone activates CFTR, but not ClC-2, via the prostaglandin receptor (EP(4)).

Authors:  Yohei Norimatsu; Aurelia R Moran; Kelvin D MacDonald
Journal:  Biochem Biophys Res Commun       Date:  2012-08-29       Impact factor: 3.575

10.  Extracellular nucleotides inhibit oxalate transport by human intestinal Caco-2-BBe cells through PKC-δ activation.

Authors:  Ruhul Amin; Sapna Sharma; Sireesha Ratakonda; Hatim A Hassan
Journal:  Am J Physiol Cell Physiol       Date:  2013-04-17       Impact factor: 4.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.